3
|
Borowski E, Poppe A, Laenen A, Remmerie C, Van Asten K, Nevelsteen I, Smeets A, Weltens C, Peeters S, Leunen K, Berteloot P, Amant F, Vergote I, Van Limbergen E, Christiaens MR, Wildiers H, Floris G, Poppe W, Neven P. Abstract P6-09-12: Breast cancer characteristics and the levonorgestrel intrauterine device. A monocentric retrospective study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-09-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
OBJECTIVE: The levonorgestrel-intrauterine device (LNG-IUD) is a widely used contraceptive method. It is not clear if LNG-IUD users are more likely to develop breast cancer. Breast cancer growth through the estrogen and/or the human epidermal growth factor receptor 2 (HER2) pathway could be influenced by a continuous low systemic dose of levonorgestrel. In this study, we compare breast cancer characteristics and the receptor expression of estrogen (ER), progesterone (PR) and HER2 in women with and without a LNG- IUD at the time of diagnosis.
METHODS: In this retrospective, observational study, we included 2599 consecutive breast cancer patients who were younger than 55 years at diagnosis and treated between 2000 and 2014 in the University Hospitals Leuven for a primary invasive, non-metastatic tumor. The non LNG-IUD group was matched by age and parity at diagnosis. ER, PR and HER2 status were reported according to ASCO/CAP guidelines. The Chi-square test was used to compare receptor status between groups. All tests were two-sided, and a 5% significance level was assumed. An additional analysis was performed to detect the occurrence of HER 2 expression with or without intake of oral contraception by diagnosis in the control group.
RESULTS: 366 LNG-IUD users and 2233 women without a LNG-IUD were included. Compared to the control group, the LNG-IUD users had a lower Nottingham prognostic index (4.2 vs 4.4; p=0.048), more PR expression (79.2% vs 73.4%; p=0.021) but less HER2 expression (11.6% vs 17.2%; p=0.009). A significant higher rate of ER+PR+HER2- was observed in the LNG-IUD group (63.26 % vs 73.46%; p<0.001). These differences in receptor expression were mainly observed in the age group 45-49 years at diagnosis. Additionally, a trend of more HER2 positivity associated with oral contraceptive use was noticed in the control group.
CONCLUSION: We found in a breast cancer population, matched for age and parity, significant differences in the PR and HER2 expression according to use of LNG-IUD at time of diagnosis. ER positive, PR positive and HER2 negative breast cancers are more frequently seen in LNG-IUD users. There is a trend of less HER 2 positivity in LNG-IUD users and it is more common seen in oral contraception users.
Citation Format: Borowski E, Poppe A, Laenen A, Remmerie C, Van Asten K, Nevelsteen I, Smeets A, Weltens C, Peeters S, Leunen K, Berteloot P, Amant F, Vergote I, Van Limbergen E, Christiaens M-R, Wildiers H, Floris G, Poppe W, Neven P. Breast cancer characteristics and the levonorgestrel intrauterine device. A monocentric retrospective study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-09-12.
Collapse
Affiliation(s)
- E Borowski
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - A Poppe
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - A Laenen
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - C Remmerie
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - K Van Asten
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - I Nevelsteen
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - A Smeets
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - C Weltens
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - S Peeters
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - K Leunen
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - P Berteloot
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - F Amant
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - I Vergote
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - E Van Limbergen
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - M-R Christiaens
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - H Wildiers
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - G Floris
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - W Poppe
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| | - P Neven
- University Hospitals Leuven, Leuven, Vlaams Brabant, Belgium; Catholic University Leuven, Leuven, Vlaams Brabant, Belgium
| |
Collapse
|
11
|
Van Asten K, Dieudonné AS, Lintermans A, Blomme C, Brouckaert O, Lambrechts D, Wildiers H, Christiaens MR, Timmerman D, Van Calster B, Decloedt J, Berteloot P, Verhoeven D, Joerger M, Zaman K, Dezentjé V, Neven P. Abstract OT3-2-04: Prospective multicenter study evaluating the effect of impaired tamoxifen metabolization on efficacy in breast cancer patients receiving tamoxifen in the neo-adjuvant or metastatic setting - The CYPTAM-BRUT 2 trial. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-ot3-2-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Tamoxifen is often used for the prevention and treatment of hormone receptor positive breast cancer. It is a prodrug which is metabolized by human liver enzymes to more active metabolites. The principal active metabolite of tamoxifen is considered to be endoxifen, which is formed by cytochrome P450 (CYP) enzymes. These enzymes are highly polymorphic in humans and endoxifen plasma levels are modulated by the patient's genotype. The effect of lowered endoxifen plasma levels on tamoxifen efficacy, however, is not yet clear as results remain contradictory. However, the association between endoxifen plasma concentrations, multiple CYP-genotypes and clinical outcome has not been studied so far in a prospective study in patients with advanced breast cancer receiving first-line tamoxifen treatment.
Trial design
CYPTAM-BRUT 2 is a prospective multicenter open-label single-arm non-randomized observational trial approved by the UZ Leuven Ethics Committee. Eligibility criteria are postmenopausal women with estrogen receptor positive invasive breast cancer receiving tamoxifen as first-line therapy in the metastatic or neo-adjuvant setting. Prior adjuvant endocrine therapy is allowed if there is more than 12 months after completion of the adjuvant therapy.
Primary endpoint is the association between endoxifen steady-state plasma concentrations and objective response rate after 3-6 months of treatment using RECIST criteria. Main secondary endpoint is the relation between endoxifen plasma concentrations and clinical benefit (CR+PR+SD at 6 months) according to the RECIST criteria. Other secondary endpoints include progression-free survival, toxicity and the association between CYP2D6 genotype and clinical outcome. In addition, we will assess how much of the variation in endoxifen levels is explained by the genetic variants and CYP2D6 inhibitors.
The trial is designed to detect a statistical association between endoxifen and objective tumor response rate (ORR), under the assumption that the relationship is linear with an odds ratio (OR) of 1.49 per 10 nmol/l. Using available data on endoxifen concentrations, this OR is chosen to reflect an improvement from 10% ORR in the lowest endoxifen quartile to 30% in the highest endoxifen quartile when the overall ORR is around 18%. To have 90% power at a 5% significance level, 180 patients have to be included into the study. The main secondary study endpoint is clinical benefit at 6 months. The study has to include 243 patients to detect a statistically significant association with endoxifen with 80% power at a 5% significance level, assuming an OR of 1.28 per 10 nmol/l. This OR is chosen to reflect an improvement of clinical benefit at 6 months from 30% in the lowest endoxifen quartile to 50% in the highest endoxifen quartile (overall clinical benefit around 39%).
Patient accrual
Currently 257 patients from 22 participating centers in Belgium and Switzerland are included (May 2013). As the sample size calculation did not account for missing data, inclusions will continue until 243 patients who fulfill the inclusion criteria are included (i.e. target lesions, blood sample and response evaluation).
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr OT3-2-04.
Collapse
Affiliation(s)
- K Van Asten
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - A-S Dieudonné
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - A Lintermans
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - C Blomme
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - O Brouckaert
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - D Lambrechts
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - H Wildiers
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - M-R Christiaens
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - D Timmerman
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - B Van Calster
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - J Decloedt
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - P Berteloot
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - D Verhoeven
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - M Joerger
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - K Zaman
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - V Dezentjé
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| | - P Neven
- KU Leuven, Oncology, Leuven, Belgium; University Hospitals Leuven, Leuven, Belgium; KU Leuven, Vesalius Research Center and VIB, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, General Medical Oncology and Multidisciplinary Breast Center, Leuven, Belgium; KU Leuven, Oncology, & University Hospitals Leuven, Surgery and Multidisciplinary Breast Center, Leuven, Belgium; AZ Sint-Blasius, Gynecology, Dendermonde, Belgium; AZ Sint-Maarten, Gynecology and Obstetrics, Duffel, Belgium; AZ Klina, Medical Oncology, Brasschaat, Belgium; Cantonal Hospital, Medical Oncology and Clinical Pharmacology, St-Gallen, Switzerland; University Hospital CHUV, Breast Center, Lausanne, Switzerland; Leiden University Medical Center, Clinical Oncology and Clinical Pharmacy and Toxicology, Leiden, Netherlands; KU Leuven, Oncology, & University Hospitals Leuven, Gynecology and Obstetrics and Multidisciplinary Breast Center, Leuven, Belgium
| |
Collapse
|